Stocks to Buy based on the Best Stock Market Research
Pulmatrix (PULM) stock has been very active lately and should be watched daily for the next few months. Shares of PULM are usually very active and provide nice trading opportunities to those who are patient.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF). In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD). Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
PULM stock soared on Friday but then fell in after hours after the company announced they will be selling up to $11 million in stock. While this is not guaranteed, PULM should find a buyer in the $2.50-$3 range right now which is where the stock has solid support.
Anything below $2.50 is a strong speculative buy for a trade.